


## Four Key Components of Our Corporate Strategy

# Progress of the Four Key Components

“Our aspiration is to become a globally-leading medtech company contributing to people’s lives by delivering innovative solutions that benefit patients, healthcare professionals, payors and providers.” This is Olympus’ strategic aspiration under the corporate strategy, which aims to achieve an operating margin of over 20% for the fiscal year 2023. To achieve this target, we are promoting various initiatives.



**COMPONENT A**

- **Divestiture of Imaging Business**  
Olympus initiated the process to split off the Imaging business and transfer it to a special purpose company managed and operated by Japan Industrial Partners Inc., and a final agreement was concluded on September 30, 2020.
- **Transfer of Norwalk Facility in United States**  
The Norwalk facility in the United States is one of the manufacturing sites for therapeutic devices. On August 6, 2020, an agreement was concluded with Nissha Co. Ltd. on the transfer of the Norwalk facility to Nissha Medical Technologies.

**COMPONENT C**

- **Successfully launched Soltive™ SuperPulsed Laser System providing physicians and patients with breakthrough performance in kidney stone management**
- **Grew the overall Olympus GI-Endotherapy, portfolio with launches in ERCP, ESD, Hemostasis and the acquisition of Arc Medical Design including the innovative ENDOCUFF™ portfolio**

**COMPONENT B**

- **Launched EVIS X1, next-generation gastrointestinal endoscopy system, in EMEA, Japan, Australia, India and Hong Kong**
- **Finalizing AI system for CAD (detection and characterization) applications in GI endoscopy**

**COMPONENT D**

- **Research and development of Advanced Information-Assisted Endoscopic Surgery System selected as a subsidized project by the Japan Agency for Medical Research and Development (AMED)**